There is provided a nanobody against Von Willebrand Factor (vWF) consisting of4framework regions, FR1 to FR4, and 3 complementarity determining regions, CDR1to CDR3, wherein:CDR1 comprises a sequence that has 0 or 1 amino acid difference across theentire lengththereof compared to YNPMG；CDR2 comprises a sequence that has 0 to 2 amino acid differences across thelength thereofcompared to the sequence selected from the group consisting of:AISRTGGSTYYPDSVEG,AISRTGGSTYYARSVEG, SISWSGTYTAYSDNVKG, GISWSGVSTDYAEFAKG, SISWSGSYTAYADNVKG,SISWSGMSTYYTDSVKG, TITSGGRTSYADSVKG, AISWSGGLTYYADSVKG, TITSGGSTNYADPVKG, andTITSGGSTNYADSVKG； andCDR3 comprises a sequence that has 0 to 2 amino acid differences across thelength thereofcompared to the sequence selected from the group consisting of:AGVRAEDGRVRTLPSEYTF,AGVRAEDGRVRSLPSEYTF, AGVRAEDGRVRTLPSEYNF, QSRYRSNYYDHDDKYAY, LGRYRSNWRNIGQYDY,QSRYSSNYYDHDDKYAY, SNRYRTHTTQAMYNY, VVDGKRAP, NRRQKTVQMGERAYDY,NLKQGSYGYRFNDY, and NLKQGDYGYRFNDY.There is also provided nucleic acids encoding, host cells capable ofexpressing, compositionscomprising, uses of, and methods of producing said nanobodies.
